Skip to content
TILs, Olutasidenib, T-DXd episode artwork

Dec 8, 2022 17 min

TILs, Olutasidenib, T-DXd

from OncoPharm Hosted by John Bossaer

Tumor-Infiltrating Lymphocytes (TILs) getting closer to entering practice. Updated survival results published from DESTINY-Breast03 (T-DXd vs. T-DM1). A new IDH1 inhibitor, olutasidenib, is FDA-approved for relapsed or refractory AML.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

TILs, Olutasidenib, T-DXd

0:00 17:52

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OncoPharm?

This episode is 17 minutes long.

When was this OncoPharm episode published?

This episode was published on December 8, 2022.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.